Sartorius Stedim Biotech paid $825 million for part of Danaher’s life sciences business in a deal that included chromatography hardware, industrial skids, resins, and single-use tangential flow filtration (TFF) systems. The company reportedly also hired 300 Danaher staff. The sale was prompted by U.S. regulators, who only approved Danaher’s acquisition of GE’s Biopharma business on the condition it agreed to divest certain assets.1 Danaher completed the takeover of the GE business—since renamed Cytiva—on March 30. Source: Genetic Engineering News 12/5/2020